Effectiveness of Tirofiban in Patients Undergoing Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction: A Meta-Analysis of Randomized Clinical Trials

Abstract

Whether or whether or not tirofiban is beneficial within side the quick time period for sufferers with STEMI who go through PCI is debatable. A meta-analysis validated the short-term efficacy and safety of tirofiban in patients with ST-phase elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). Comparing STEMI patients undergoing PCI with and without tirofiban. We found all relevant randomised controlled trials by searching scientific databases and websites. This fixed-results model computed RR and 95% CI. 10 RCTs included 5008 people. After 30 days, death from any cause (RR 0.79, CI 0.55-1.12, P=0.18), major bleeding (1.37, 0.93-2.03, P=0.11), or transfusion (1.23, 0.94-1.61, P=0.13) were no longer impacted. Minor bleeding (1.29, 1.02-1.63, P=0.04), thrombocytopenia (2.04, 1.40-2.97, P=0.0002), and 6-month all-purpose mortality (0.57, 0.36-0.90, P=0.02) showed statistically significant differences. Repeat revascularization (0.58, 0.43-0.78, P=0.0004) and myocardial infarction (0.55, 0.33-0.92, P=0.02) also differed. Mild bleeding and thrombocytopenia are more common with tirofiban, although reinfarction, revascularization, and death after 6 months are decreased.